Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
NIH Fogarty
Eligibility
Inclusion criteria
Inclusion criteria: Tumor samples obtained from a previously collected breast cancer tissue cohort in the laboratory. Primary treatment na?ve Breast Cancer patients under 45 years with information on childbirth, clinicopathological features and follow up on disease outcome will be included.
Exclusion criteria
Exclusion criteria: NACT Neo adjuvant chemotheraphy, Missing childbirth information, Patients above 45 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of distinct spatial gene expression patterns and immune/stromal signatures in postpartum breast cancer (PPBC) tumors using spatial profiling that are associated with poor clinical outcomes (e.g., recurrence, metastasis, or reduced overall survival).Timepoint: The duration of the primary Outcome will be Nine Months. Total Study Duration twelve Months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Validation of key biomarkers using multiplex immunohistochemistry mIHC Comparison of tumor microenvironment between PPBC post partum breast cancer and nonPPBC patients Evaluation of biomarkers prognostic value for identifying high risk PPBC patients Timepoint: Three Months after primary Outcome | — |
Countries
India
Contacts
Public ContactDr Jyothi S Prabhu
St Johns Research Institute Bengaluru
Outcome results
None listed